Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
- Pursuing Divestiture of CertainT® Platform, Implements Changes to Corporate Leadership -- Build-out of GMP Manufacturing Facility to be Completed...